KR101824770B1 - Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract - Google Patents
Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract Download PDFInfo
- Publication number
- KR101824770B1 KR101824770B1 KR1020150103987A KR20150103987A KR101824770B1 KR 101824770 B1 KR101824770 B1 KR 101824770B1 KR 1020150103987 A KR1020150103987 A KR 1020150103987A KR 20150103987 A KR20150103987 A KR 20150103987A KR 101824770 B1 KR101824770 B1 KR 101824770B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- cosmetic composition
- skin
- wrinkles
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 239000000284 extract Substances 0.000 title claims abstract description 57
- 239000002537 cosmetic Substances 0.000 title claims abstract description 34
- 241001289529 Fallopia multiflora Species 0.000 title claims description 3
- 230000001153 anti-wrinkle effect Effects 0.000 title description 2
- 230000037303 wrinkles Effects 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 238000009472 formulation Methods 0.000 claims description 31
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 5
- 239000000686 essence Substances 0.000 claims description 2
- 206010040954 Skin wrinkling Diseases 0.000 claims 3
- 239000006228 supernatant Substances 0.000 claims 2
- 241000512694 Corallus Species 0.000 claims 1
- 239000002024 ethyl acetate extract Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 40
- 238000012360 testing method Methods 0.000 abstract description 22
- 102000029816 Collagenase Human genes 0.000 abstract description 21
- 108060005980 Collagenase Proteins 0.000 abstract description 21
- 229960002424 collagenase Drugs 0.000 abstract description 20
- 241000411851 herbal medicine Species 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 14
- 102000016387 Pancreatic elastase Human genes 0.000 abstract description 13
- 108010067372 Pancreatic elastase Proteins 0.000 abstract description 13
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 231100000989 no adverse effect Toxicity 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 206010040880 Skin irritation Diseases 0.000 description 11
- 230000003078 antioxidant effect Effects 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 231100000475 skin irritation Toxicity 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 230000036556 skin irritation Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000002000 scavenging effect Effects 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000002038 ethyl acetate fraction Substances 0.000 description 6
- 230000007760 free radical scavenging Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229940087168 alpha tocopherol Drugs 0.000 description 5
- JTEDVYBZBROSJT-UHFFFAOYSA-N indole-3-butyric acid Chemical compound C1=CC=C2C(CCCC(=O)O)=CNC2=C1 JTEDVYBZBROSJT-UHFFFAOYSA-N 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 231100000430 skin reaction Toxicity 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229960000984 tocofersolan Drugs 0.000 description 5
- 229940096998 ursolic acid Drugs 0.000 description 5
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 5
- 239000002076 α-tocopherol Substances 0.000 description 5
- 235000004835 α-tocopherol Nutrition 0.000 description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 239000005708 Sodium hypochlorite Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000005499 Sasa Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GEWDNTWNSAZUDX-WQMVXFAESA-N (-)-methyl jasmonate Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-WQMVXFAESA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 244000061520 Angelica archangelica Species 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000005667 attractant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001728 capsicum frutescens Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 230000031902 chemoattractant activity Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940096118 ella Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003617 indole-3-acetic acid Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- GEWDNTWNSAZUDX-UHFFFAOYSA-N methyl 7-epi-jasmonate Natural products CCC=CCC1C(CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000006870 ms-medium Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241001282110 Pagrus major Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 241000206609 Porphyra Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 244000066511 Solanum xanthocarpum Species 0.000 description 1
- 235000017622 Solanum xanthocarpum Nutrition 0.000 description 1
- 244000002968 Tamarix aphylla Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 생약재 추출물을 함유하는 인체 피부주름 예방 및 개선 기능성 화장료 조성물 및 그 추출 방법에 관한 것으로 적하수오 부정근으로부터 추출된 유효성분을 함유하는 것을 특징으로 하는 피부주름 예방 및 개선 기능성 화장료 조성물을 제공하며 나아가 인체 피부의 항산화, 엘라스테이즈 활성저해, 콜라게네이즈 발현저해 및 피부주름개선 임상시험에서 우수한 효과를 발휘할 뿐만 아니라 피부에 부작용이 없는 동시에 피부주름개선 효과가 뛰어난 효과를 제공한다.The present invention relates to a functional cosmetic composition for prevention and improvement of wrinkles of human skin containing a herbal medicine extract and a method of extracting the same, and provides a cosmetic composition for preventing and improving skin wrinkles, which comprises an active ingredient Furthermore, it exhibits excellent effects in clinical tests of antioxidation, inhibition of elastase activity, inhibition of collagenase expression and wrinkle of skin of human body, as well as having no adverse effect on the skin, and also has an excellent effect of improving skin wrinkles.
Description
본 발명은 적하수오 조직배양결과 얻은 부정근 추출물을 유효성분으로 함유하는 피부주름개선용 화장료 조성물 및 그 제조방법에 관한 것이다.
The present invention relates to a cosmetic composition for improving skin wrinkles containing an adriamycin root extract obtained as a result of an in vitro hypotonic tissue culture as an active ingredient, and a process for producing the same.
인체의 피부는 노화 과정에서 다양한 물리화학적인 변화가 일어난다. 그 원인으로는 크게 내적인 노화(intrinsic aging)와 광노화(photo-aging)로 구분되며 이에 관한 연구가 활발히 이루어져 왔다. 자외선, 스트레스, 질병 상태, 환경 인자, 상처, 나이가 들어감에 따라 프리라디칼이 활성화되어 야기될 수 있으며, 이런 상태가 심화될 경우 생체 내에 존재하는 항산화 방어망을 파괴하고, 세포 및 조직을 손상시켜 성인병 및 노화를 촉진하게 된다. The skin of the human body undergoes various physico-chemical changes during the aging process. The cause of this phenomenon is divided into intrinsic aging and photo-aging. Free radicals can be caused by activation of ultraviolet rays, stress, disease state, environmental factors, wounds, and aging. If such state is deepened, the antioxidant defense network existing in the living body is destroyed, And aging.
한편, 노화에는 이러한 프리라디칼 뿐만 아니라 콜라겐 분해효소인 기질 금속 단백질 분해 효소(Matrix Metalloproteinase; MMP)라는 효소도 관여한다. 즉, 생체 내에서 콜라겐과 같은 세포외 기질의 합성과 분해는 적절하게 조절되고 있는데, 노화가 진행되면서 콜라겐 합성이 감소하고, 콜라겐을 분해하는 효소인 기질 금속단백질 분해 효소(MMP)의 발현이 촉진되어 피부의 탄력이 저하되고 주름이 형성된다. 또한, 자외선 조사에 의해서도 이러한 분해 효소가 활성화되기도 한다.On the other hand, enzymes such as Matrix Metalloproteinase (MMP), which is a collagenase, are involved in aging as well as these free radicals. That is, the synthesis and degradation of extracellular matrix such as collagen in vivo is appropriately controlled. As the aging progresses, collagen synthesis decreases and promotes expression of collagen-degrading enzyme substrate metalloproteinase (MMP) And the elasticity of the skin is lowered and wrinkles are formed. These degrading enzymes are also activated by ultraviolet irradiation.
본 발명의 피부주름개선 기능성 화장료 조성물을 구성하는 생약재 추출물의 제조에 사용되는 적하수오(赤何首烏, Polygonum multiflorum Thunberg)는 마디풀과에 속하는 다년생 만년 초본이며, 뿌리를 자른 면은 엷은 유황색 또는 갈색으로서, 원형의 특이한 무늬를 이루고 있으며 국내에서는 전남, 경남북, 충북, 강원, 경기, 함남 지방 등 각지에 분포되었고, 중국, 일본 및 한국에서 가장 유명한 강장제 중의 하나로 알려져 있다. The Polygonum multiflorum Thunberg used in the preparation of the extract of herbal medicines constituting the functional cosmetic composition for improving skin wrinkles of the present invention is a perennial herbaceous plant belonging to the genus Porphyra, and the root-cut surface is pale yellow or brown It is distributed in Jeonnam, Kyungnam North, Chungbuk, Gangwon, Gyeonggi and Hamnam provinces in Korea and it is known as one of the most famous tonic drugs in China, Japan and Korea.
적하수오추출물과 관련된 선행기술로는 피부미백과 관련하여 대한민국 공개특허 제10-2009-0120810호, 대한민국 등록특허 제10-1052189호가 공지되어 있고 피부노화와 관련하여서는 대한민국 등록특허 제10-0829846호가 공지되어 있다. 또, 대한민국 등록특허 제10-0966835호에는 감초, 승마, 하수오, 흑임자, 상황버섯, 당귀, 상백피, 백작약, 고삼, 황금으로 구성되어진 식물혼합 추출물이 미백 및 항주름 효과가 있다는 사실이 개시되어 있고 대한민국 등록특허 제10-1178594호에는 하수오추출물, 대추추출물 및 황촉규추출물을 함유하는 보습 및 항산화 효과의 화장료 조성물에 대하여 개시된 바 있다. 또한, 적하수오 추출물을 함유하는 피부주름개선 기능성 화장료 조성물(특허출원 제10-2013-0055367, 적하수오 추출물을 함유하는 피부주름 개선 기능성 화장료 조성물)에 대한 연구가 진행되었다.
Prior art related to the extract of Sasa extract is disclosed in Korean Patent Laid-Open No. 10-2009-0120810 and Korean Patent No. 10-1052189 in relation to skin whitening, and Korean Patent No. 10-0829846 is disclosed in connection with skin aging . Korean Patent No. 10-0966835 also discloses that plant mixture extracts composed of licorice, horse riding, seaweed, black shoemaker, mushroom, angelica, angelica, mulberry, white peony, gosam and gold have a whitening and anti-wrinkle effect Korean Patent No. 10-1178594 discloses a cosmetic composition having a moisturizing and antioxidative effect, which comprises an extract of Sasa extract, a jujube extract, and a extract of Hwangryeokgi. In addition, studies have been conducted on a skin wrinkle-improving functional cosmetic composition containing an enemy Sucrose extract (Patent Application No. 10-2013-0055367, functional cosmetic composition for improving skin wrinkles containing an extract of an antiseptic).
그러나 현재까지 적하수오의 조직배양 및 그의 산물에 대한 연구는 전무한 실정이며 적하수오의 조직배양 결과 얻은 부정근의 추출물 또는 그의 분획물을 유효성분으로 함유하는 화장료 조성물에 대하여는 상기 선행기술의 어디에도 암시되거나 개시된 바 없다.However, there have been no studies on the tissue culture of the red pepper and its products until now, and the cosmetic composition containing the extract of the adventitious roots obtained as a result of the tissue culture of red pepper or its fraction as an active ingredient has been disclosed in any of the aforementioned prior arts none.
식물의 조직배양은 기관의 조직이나 세포를 식물체로부터 분리하여 적당한 환경조건하에서 무균적으로 배양하여 식물체로서 완전한 기능을 갖는 개체로 재생시키는 일련의 기술을 말한다. 조직배양의 장점으로 바이러스가 없는 개체를 얻을 수 있고, 유전적으로 특이한 새로운 특성을 가진 식물체를 분리해 낼 수 있으며, 일정한 식물체를 단시간 내에 대량으로 번식시킬 수 있으며, 좁은 실내에서도 연중 증식이 가능함과 동시에 육종 연한을 단축시킬 수 있다는 장점이 있다. 조직배양의 방법에는 완전식물체배양, 배배양, 기관배양, 캘러스배양, 단일세포배양, 원형질체배양 등이 공표되어 있다.
Tissue culture of a plant refers to a series of techniques in which tissue or cells of an organ are separated from the plant, cultured aseptically under appropriate environmental conditions, and regenerated as a full-functioning plant as a plant. The advantage of tissue culture is that it can obtain a virus-free individual, isolate plants with novel characteristics that are genetically unique, propagate a large number of plants in a short time, and grow in a narrow room year-round It has the advantage of shortening the breeding period. Methods of tissue culture include complete plant culture, embryo culture, organ culture, callus culture, single cell culture, protoplast culture, and the like.
따라서 본 발명의 목적은 식물조직배양기술과 생물반응기를 이용하여 얻은 적하수오 부정근 추출물을 유효성분으로 함유하는 피부주름개선 기능성 화장료 조성물을 제공하는데 있다. Accordingly, it is an object of the present invention to provide a cosmetic composition for improving skin wrinkles containing plant extracts of T. orientalis obtained by plant tissue culture technology and a bioreactor as an active ingredient.
본 발명의 다른 목적은 피부에 부작용을 초래하지 않고, 피부자극이 없이 안전하며, 항산화, 엘라스테이즈 활성저해, 콜라게네이즈 발현저해 효과가 뛰어난 피부주름개선 기능성 화장료 조성물을 이용한 다양한 제형을 제공하는데 있다.
Another object of the present invention is to provide various formulations using a cosmetic composition for improving skin wrinkles which is safe without skin irritation, has no side effects on the skin, and is excellent in antioxidation, inhibition of elastase activity and inhibition of collagenase expression have.
본 발명의 상기 목적은 본 발명은 피부 주름개선 효과를 갖는 적하수오 부정근 추출물을 유효성분으로 포함하는 화장료 조성물을 제공한다.The above object of the present invention is to provide a cosmetic composition comprising, as an active ingredient, an aqueous extract of red sea bream which has a skin wrinkle-reducing effect.
(a) 적하수오의 뿌리로부터 무균상태의 기내 유도배지로부터 부정근을 유도하는 단계와; (b) 상기 단계에서 얻은 적하수오 부정근을 소정의 추출용매를 가하여 추출하는 단계와; (c) 상기 단계에서 수득한 추출물에 분획용 유기용매를 가하여 분획하는 단계를 포함하는 것을 특징으로 한다.(a) deriving adventitious roots from an aseptic in-cabinet induction medium from a roots of enemy sewage; (b) extracting the aqueous sodium hypochlorite obtained in the above step by adding a predetermined extraction solvent; (c) fractionating the extract obtained in the above step by adding an organic solvent for fractionation.
여기서, 상기(a)단계의 부정근 유도는 당업계에서 통상적으로 이용되는 방법으로 수행될 수 있다. 상기 부정근 유도 배지는 일반적으로 사용되고 있는 배지가 있다면, 특별한 제한없이 사용이 가능하다. 바람직하기로는 SH (Schenk and Hildebrandt), MS (Murashige &Skoog, 1962) 배지 또는 화이트 배지(White 배지)를 이용하는 것이 바람직하나 단지 이에만 한정되는 것은 아니다. 본 발명에서 부정근 유도배지에 병용할 수 있는 식물 생장조절제는 IBA (indole butyric acid), IAA (indole acetic acid), NAA (naphthalene acetic acid), GA (gibberellin) 또는 BAP (benzyl amino purine) 등이 첨가될 수 있으나, 이들에 특히 제한되지는 않는다. 또 유인제로서는 생리활성물질을 증가시킬 수 있는 자극이라면 화학적 혹은 물리적인 유인제가 될 수 있으며, MJ (Methyl jasmonate) 및 SA (Salicylic acid) 등이 첨가될 수 있으며 특별히 이에 제한되지는 않는다. 상기 배지에 첨가되는 상기 성분들의 함량은 본 발명의 효과를 달성할 수 있는 범위 내에서 변동될 수 있다는 것은 당업자가 용이하게 인식할 수 있다.Herein, the induction of the coronoid root in the step (a) may be performed by a method commonly used in the art. The adventitious root induction medium can be used without any particular limitation, if there is a commonly used medium. Preferably, it is preferable to use SH (Schenk and Hildebrandt), MS (Murashige & Skoog, 1962) medium or white medium (White medium). In the present invention, plant growth regulators that can be used in conjunction with the adventitious root induction medium include indole butyric acid (IBA), indole acetic acid (IAA), naphthalene acetic acid (NAA), gibberellin (GA) or benzyl amino purine But is not limited thereto. In addition, as an attractant, a stimulus that can increase physiologically active substances may be a chemical or physical attractant, and MJ (Methyl jasmonate) and SA (salicylic acid) may be added, and the present invention is not particularly limited thereto. It will be readily appreciated by those skilled in the art that the content of the components added to the medium can be varied within a range that can achieve the effects of the present invention.
상기 (a)단계에서 부정근은 생체중 기준으로 1~20 g/L로 접종할 수 있으며, 바람직하게는 5 g/L로 접종할 수 있다.In the step (a), the adventitious roots can be inoculated at a dose of 1 to 20 g / L, preferably 5 g / L, based on living body weight.
상기 (b)단계에서 추출용매는 정제수, 탄소수 1 내지 4인 무수 또는 함수 메탄올, 에탄올, 프로필알코올, 부틸알코올, 글리세린, 프로필렌글라이콜 및 부틸렌글라이콜을 포함한 용매군 중에서 선택된 어느 하나의 순수용매 또는 둘 이상이 조합된 혼합용매가 이용되며, 상기 약재에 가해지는 추출용매는 상기 약재 전체 부피 대비 1 내지 20배의 양이면 바람직하다. 또한, 상기 추출용매를 가한 후 진행되는 추출공정은, 5 내지 37℃의 온도조건에서 1 내지 15일간 침적 추출하는 침지법, 냉각콘덴서를 장착시킨 후 50 내지 95℃의 온도조건에서 4 내지 20시간동안 가열 추출하는 환류 냉각법 또는 30 내지 60℃의 온도조건에서 4 내지 20시간 동안 초음파 조사를 수행하여 추출하는 초음파추출법 중에서 선택하여 병행할 수도 있다.In the step (b), the extraction solvent may be any one selected from the group consisting of purified water, a solvent selected from the group consisting of anhydrous or hydrous methanol having 1 to 4 carbon atoms, ethanol, propyl alcohol, butyl alcohol, glycerin, propylene glycol and butyleneglycol Solvent or a combination of two or more thereof is used, and the extraction solvent added to the medicament is preferably 1 to 20 times the total volume of the medicament. The extraction step after the extraction solvent is added is carried out by a dipping method in which dipping extraction is carried out at a temperature of 5 to 37 ° C for 1 to 15 days and a dipping method in which a cooling condenser is mounted and then heated at a temperature of 50 to 95 ° C for 4 to 20 hours Or by an ultrasonic extraction method in which ultrasonic irradiation is performed for 4 to 20 hours at a temperature of 30 to 60 캜 for extraction.
상기 (c)단계에서 사용되는 분획용 유기용매로는 에틸아세테이트, 디에틸에테르, 트리클로로메탄 및 부틸알코올 중에서 선택된 유기용매 단독 또는 이들을 혼합하여 사용될 수 있다.The organic solvent for the fraction used in step (c) may be an organic solvent selected from ethyl acetate, diethyl ether, trichloromethane and butyl alcohol, or a mixture thereof.
한편, 상기 본 발명 방법에 따라 수득한 상기 적하수오 부정근 추출물을 화장료에 적용하는 경우에는 화장료 전체 조성물 중량을 기준으로 0.001 내지 10중량%이면 피부 주름개선에 충분한 효과를 발휘할 수 있다. 상기 추출된 화장료 유효성분의 함량이 전체 화장료 중량대비 0.001중량% 미만인 경우에는 본래 목적하는 효과를 충분하게 달성할 수 없어 바람직하지 못하며, 상기 추출된 화장료 유효성분의 함량이 전체 화장료 중량대비 10중량%를 초과하는 경우에는 화장료의 안정성에 문제를 발생시킬 수 있으며, 이로 인하여 화장료의 외관이나 사용시 충분한 화장효과를 발현시킬 수 없는 단점으로 인해 바람직하지 못하다.On the other hand, when the extract of the present invention obtained by the method of the present invention is applied to cosmetics, the effect of improving the skin wrinkles can be exerted in an amount of 0.001 to 10% by weight based on the total weight of the cosmetic composition. When the content of the extracted active ingredient is less than 0.001% by weight based on the total weight of the cosmetic composition, the desired effect can not be sufficiently attained. Therefore, when the content of the extracted active ingredient is less than 10% , There is a problem in the stability of the cosmetic composition, which is not preferable due to the disadvantage that the appearance of the cosmetic composition and sufficient cosmetic effects can not be exhibited.
본 발명은 적하수오 부정근 추출물의 용매분획물, 특히 에칠아세테이트 분획물이 안전하면서도 피부주름개선에 유용하다는 발견에 기초한다.The present invention is based on the discovery that the solvent fractions, especially the ethyl acetate fraction, of the crude Sucrose root extract are safe and useful for improving skin wrinkles.
본 발명에 따르면 적하수오 부정근 추출물로부터 항산화, 엘라스테이즈 활성저해, 콜라게네이즈 발현저해 효과 및 피부주름개선 효과가 있는 유효성분을 추출하여 이를 유효성분으로 하는 화장료 조성물을 제공하고 특히 피부주름개선을 위해 다양한 제형으로 사용될 수 있으며, 예컨대 스킨류, 로션류, 에센스류, 크림류, 팩류, 파운데이션류 및 메이크업베이스류와 같은 다양한 상품 유형으로 제조될 수 있다. 물성적인 측면에서는 액상, 크림상, 페이스트상 및 고체상 등 다양한 성상으로 적용가능하며, 통상적인 화장료 제조법에 적용시킬 수 있음은 또한 자명하다.
According to the present invention, there is provided a cosmetic composition comprising, as an active ingredient, an active ingredient having an antioxidative activity, an inhibitory effect on elastase activity, an inhibitory effect on collagenase expression and a skin wrinkle effect, And may be manufactured in various types of products such as skins, lotions, essences, creams, packs, foundations, and makeup bases. In terms of physical properties, it can be applied to various properties such as liquid phase, cream phase, paste phase and solid phase, and it is also apparent that the present invention can be applied to a conventional method for producing cosmetic cosmetics.
본 발명 적하수오 부정근 추출물을 유효성분으로 함유하는 화장료 조성물은 항산화, 엘라스테이즈 활성저해 및 콜라게네이즈 발현저해 활성에 뛰어난 효과가 있다.
The cosmetic composition containing the extract of the present invention as an active ingredient has an excellent effect on antioxidation, inhibition of elastase activity and inhibition of collagenase expression.
이하, 본 발명을 구체적으로 설명하기 위해 실시예, 실험예 등의 구체적인 예를 들어 설명하기로 한다. 그러나 본 발명에 따른 실시예 또는 실험예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 아래에서 상술하는 예들에 한정되는 것으로 해석되어지지 않아야 한다. 본 발명에 따른 실시예 및 실험예들은 당 업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해서 제공 되어지는 것에 불과하므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.Hereinafter, specific examples of examples and experimental examples will be described in order to explain the present invention in detail. However, the embodiments or experiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the above-mentioned examples. It is to be understood that both the foregoing description and the following examples are provided for a more complete understanding of the present invention to those skilled in the art to which the present invention pertains, It should be understood that variations can be made.
이하, 본 발명의 구체적인 내용을 실시예와 실험예를 들어 상세히 설명한다.
Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.
<실시예 1> 적하수오 부정근의 유도 및 증식 ≪ Example 1 & gt ; Induction and proliferation of adventitious roots
적하수오를 4% 및 2% 차아염소산 나트륨(sodium hypochlorite)용액으로 각각 20분, 10분씩 표면 살균한 뒤 멸균수로 3회 세척하였다. 그 후 30 g/L가 첨가된 MS 배지(Murashige and Skoog)를 이용하여 무균상태의 기내 식물체를 유도하였다. 유도된 식물체를 절단하여 30 g/L가 첨가된 3/4 MS 배지에 IBA (Indole-3-butyric acid) 1 mg/L의 생장조절물질을 첨가하여 22±1℃, 암조건에서 4, 혹은 8주간 배양하였다. 배지는 1 N 수산화칼륨(KOH)을 이용하여 pH 5.8로 조정하고 공기주입량을 0.1 vvm로 하여 3 L 풍선형 생물반응기로 배양하였다. 적하수오 부정근은 세척 후 동결건조 및 열풍건조를 통해 건조하여 실험에 사용하였다.
Sodium hypochlorite solution was surface-sterilized with 4% and 2% sodium hypochlorite solution for 20 minutes and 10 minutes, respectively, and then washed three times with sterilized water. The aseptic inflorescence was then induced using MS medium (Murashige and Skoog) supplemented with 30 g / L. Inducible plants were cut, and 3 mg / L of growth regulators were added to 3/4 MS medium containing IBA (Indole-3-butyric acid) at 22 ± 1 ℃ for 4, And cultured for 8 weeks. The medium was adjusted to pH 5.8 using 1 N potassium hydroxide (KOH) and the air was injected at 0.1 vvm and cultured in a 3 L balloon bioreactor. The rats were washed and then freeze dried and dried by hot air drying.
<< 실시예Example 2> 2> 적하수오Enemy 부정근Adrenaline 추출물 제조 Extract preparation
(1) 적하수오 부정근 유기용매 추출물 (1) An organic solvent extract
건조된 적하수오 부정근 100 g에 75% 에탄올 수용액 600 mL를 가한 후 1차 열수추출하고, 용매를 여과한 후 다시 75% 에탄올 수용액 600 mL를 가하여 2차 추출하고 용매를 여과한 후, 1차 및 2차 추출물을 합하고 감압농축기를 이용하여 용매를 제거함으로써 에탄올 추출물을 얻었다.
600 g of a 75% aqueous ethanol solution was added to 100 g of dried sodium hypochlorite, and the mixture was subjected to primary hot water extraction. The solvent was filtered and then 600 mL of an aqueous 75% ethanol solution was further added thereto. The solvent was then filtered, The secondary extracts were combined and the solvent was removed using a vacuum concentrator to obtain an ethanol extract.
(2) 적하수오 부정근 에틸아세테이트 분획추출물 (2) Ethyl acetate fraction extract
상기 실시예 2-(1)에 600 mL의 물을 가하고 초음파조사를 통해 적하수오 에탄올 추출물이 고르게 분산된 현탁액을 제조한 후, 동량의 에칠아세테이트를 첨가하여 분획추출하였다. 이를 와트만(Whatman) No. 2여과지로 여과하고 감압농축기를 이용하여 농축하고, 동결건조시켜 에칠아세테이트 분획물을 얻었다.
600 mL of water was added to the above Example 2- (1), and a suspension in which the ethanolic ethanol extract was evenly dispersed by ultrasonic irradiation was prepared, followed by the fractional extraction with the same amount of ethyl acetate. This is known as Whatman No. 1. 2 filter paper, concentrated using a reduced pressure concentrator, and lyophilized to obtain an ethylacetate fraction.
(3) 적하수오 부정근 부틸알코올 분획추출물 (3) Fractional butyl alcohol fraction extract
상기 실시예 2-(1)에 600 mL의 물을 가하고 초음파조사를 통해 적하수오 에탄올 추출물이 고르게 분산된 현탁액을 제조한 후, 동량의 부틸알코올을 첨가하여 분획추출하였다. 이를 와트만(Whatman) No. 2여과지로 여과하고 감압농축기를 이용하여 농축하고, 동결건조시켜 부틸알코올 분획물을 얻었다.
600 mL of water was added to the above Example 2- (1), and a suspension in which the ethanolic ethanolic extract was evenly dispersed by ultrasonic irradiation was prepared, followed by fractional extraction with the addition of the same amount of butyl alcohol. This is known as Whatman No. 1. 2 filter paper, concentrated using a vacuum concentrator, and lyophilized to obtain a butyl alcohol fraction.
<< 실험예Experimental Example 1> 항산화효과시험 1> Antioxidant effect test
본 발명의 상기 실시예 2-(1), 2-(2), 2-(3)에 따라 수득된 적하수오 부정근 추출물에 대하여 주름의 억제 및 개선 효과 검정시험으로 항산화효과를 알아보기 위하여 자유라디칼소거실험(Free Radical Scavenging Activity Test), 활성산소(superoxide anion)소거활성실험을 실시하였다. 자유라디칼소거시험은 Kim 등(Kor. J. Pharmacogn., 24 (4), 299~303 (1993))의 방법을 변형한 것으로써, 안정한 자유라디칼인 DPPH (1,1-Diphenyl-2-picrylhydrazyl radical) (Sigma)을 사용하였다. In order to examine the antioxidative effect of the extracts of suppressing wrinkles and improving effects on the extracts of Sasa obtusa obtained according to Examples 2- (1), 2- (2) and 2- (3) of the present invention, free radicals Free Radical Scavenging Activity Test, and superoxide anion scavenging activity test. The free radical scavenging test was a modification of the method of Kim et al. (Kor. J. Pharmacogn., 24 (4), 299-303 (1993)), and a stable free radical, DPPH (1,1-Diphenyl-2-picrylhydrazyl radical) (Sigma) was used.
먼저, 0.2 mM DPPH 용액 1 mL에 상기 실시예에 따라 수득된 각각의 적하수오 부정근 추출물 각각의 시료를 메탄올에 적당한 농도로 희석하여 2 mL 혼합하고, 실온에서 10분간 방치한 후 517 nm에서 흡광도를 측정한다. First, each 1 mL of 0.2 mM DPPH solution was diluted with methanol to a suitable concentration of each of the respective extracts of the respective extracts obtained according to the above example, and 2 mL of the solution was added. After incubation at room temperature for 10 minutes, the absorbance at 517 nm .
한편, 상기 자유라디칼소거시험에서의 대조군은 시료용액 대신 메탄올을 넣어 같은 방법으로 측정하며, DPPH 용액 대신 메탄올을 넣어 생약재 추출물 시료와 대조군에 대한 각각의 색 보정값을 얻는 것으로 설정하였고, 비교군으로서 일반적인 항산화제로 잘 알려진 α-tocopherol을 사용하였다(참고문헌: Muruhan, S. 외, In vitro antioxidant activities of solanum surattense leaf extract, Asian Pacific journal of tropical biomedicine, 3(1), 28-34 (2013)). Meanwhile, the control group in the free radical scavenging test was set to add methanol instead of the sample solution, measure the same way, and add methanol instead of the DPPH solution to obtain the respective color correction values for the herbal medicine extract sample and the control group. Toxicol, a well-known α-tocopherol, was used (Muruhan, S. et al., In vitro antioxidant activities of solanum surattense leaf extract, Asian Pacific Journal of tropical biomedicine, 3 (1), 28-34 (2013) .
하기 [수학식 1]을 이용하여 자유라디칼소거율을 수치로 계산하여 하기 [표 2]에 나타내었다. 하기 [표 1]에서, IC50은 자유라디칼소거율 50%를 달성하기 위해 소요되는 시료의 농도로서 다른 성분물질과 상대적으로 비교할 때 사용하는 수치로서 값이 작을수록 소거율이 높음을 나타낸다. The free radical scavenging ratio was calculated numerically using the following equation (1), and it is shown in Table 2 below. In Table 1 below, the IC 50 is the concentration of the sample required to achieve a 50% free radical scavenging rate, which is a value used in comparison with other constituent materials. The smaller the value, the higher the erase rate.
활성산소소거실험은 Noro 등(Chen. Pharm. Bull., 31, 3984~3987 (1983))의 방법을 변형한 것으로, 활성산소(superoxide anion)소거활성평가는 잔틴/잔틴옥시다제(xanthine/xanthine oxidase)효소반응에 의한 활성산소 발생계를 이용하여 활성산소에 의한 니트로블루 테트라졸리움(nitroblue tetrazolim, NBT)의 산화에 의한 흡광도의 변화를 측정하였다. The active oxygen scavenging experiment was a modification of the method of Noro et al. (Chen. Pharm. Bull., 31, 3984-3987 (1983)), and the scavenging activity of superoxide anion was evaluated by xanthine / xanthine (NBT) oxidation by reactive oxygen species was measured by using an active oxygen generating system.
Na2CO3 2.4 mL, xanthine 0.1 mL, EDTA 0.1 mL, BSA 0.1 mL, NBT 0.1 mL, 시료 0.1 mL을 넣고 잘 혼합하여 25℃에서 10분간 정치하였다. Xanthine oxidase 0.1 mL을 넣고 25℃에서 20분간 반응시킨 후, 6 mM CuCl2를 넣어 반응을 정지시켰다. ELISA reader를 사용하여 파장 560 nm에서 흡광도를 측정하였다. Na 2 CO 3 , 0.1 mL of xanthine, 0.1 mL of EDTA, 0.1 mL of BSA, 0.1 mL of NBT, and 0.1 mL of the sample, and the mixture was mixed well and allowed to stand at 25 ° C for 10 minutes. Xanthine oxidase (0.1 mL) was added and reacted at 25 ° C for 20 minutes. Then, 6 mM CuCl 2 was added to stop the reaction. Absorbance was measured at 560 nm using an ELISA reader.
한편, 상기 활성산소소거활성시험에서의 대조군은 시료용액 대신 정제수를 넣어 같은 방법으로 측정하며, xanthine oxidase 용액 대신 정제수를 넣어 생약재 추출물 시료와 대조군에 대한 각각의 색 보정값을 얻는 것으로 설정하였고, 비교군으로서 일반적인 항산화제로 잘 알려진 α-tocopherol을 사용하였다. Meanwhile, the control group in the active oxygen scavenging activity test was set to take purified water instead of the sample solution, measure the same method, and add purified water instead of the xanthine oxidase solution to obtain the respective color correction values for the herbal medicine extract sample and the control group. Α-tocopherol, which is well known as a common antioxidant, was used.
하기 [수학식 2]를 이용하여 활성산소소거율을 수치로 계산하여 하기 [표 2]에 나타내었다. 하기 [표 1]에서, IC50은 활성산소소거율 50%를 달성하기 위해 소요되는 시료의 농도로서 다른 성분물질과 상대적으로 비교할 때 사용하는 수치로서 값이 작을수록 소거능이 높음을 나타낸다.
The active oxygen scavenging ratio was calculated numerically using the following formula (2), and the results are shown in Table 2 below. In the following Table 1, the IC 50 is a concentration of the sample required to achieve 50% of the active oxygen scavenging rate, which is a numerical value used in comparison with other component materials. The smaller the value, the higher the scavenging ability.
IC50(㎍/mL)Free radical scavenging ability
IC 50 ([mu] g / mL)
IC50(㎍/mL)Active oxygen scavenging ability
IC 50 ([mu] g / mL)
상기한 [표 1]에서 보는 바와 같이, 특히 에칠아세테이트 분획물에서 상대적으로 항산화 효과가 우수한 것으로 확인되었으며, 이러한 결과는 일반적인 항산화제로 알려진 α-tocopherol의 효과보다 더 양호한 것으로 확인되었다.
As shown in the above Table 1, it was confirmed that the ethylacetate fraction had a relatively high antioxidative effect, and this result was confirmed to be better than the effect of α-tocopherol, which is known as a general antioxidant.
<< 실험예Experimental Example 2> 2> 엘라스테이즈Ella Stays 활성저해 시험 Active inhibition test
본 발명의 상기 각 실시예에 따라 수득된 추출물을 시료로 하여 피부주름의 억제 및 개선효과 검정시험으로서 엘라스테이즈 활성저해 시험(Elastase Inhibition Activity Test)을 실시하였다. Elastase Inhibition Activity Test was conducted as a test for inhibiting and improving the wrinkles of the skin using the extract obtained according to each of the above Examples of the present invention as a sample.
엘라스틴(Elastin)을 분해하는 효소인 엘라스테이즈의 활성을 측정하는 방법으로 엘라스테이즈 기질인 N-Succinyl-Ala-Ala-Ala ρ-nitroaniline을 이용하여 ρ-nitroaniline이 분해되면서 생기는 색의 변화를 410 nm의 파장에서 흡광도를 측정함으로써 엘라스테이즈 활성을 측정하는 방법이다. 완충액은 pH 8.0, 0.267 M Trizma-HCl(Sigma), 기질액은 8.8 mM N-Succinyl-(Ala)3 ρ-nitroaniline (Sigma), 효소액은 돼지췌장 엘라스테이즈를 10 ㎍/mL (Sigma)의 농도로 사용하였다. 완충액 60 μL, 기질액 20 μL와 상기 각 실시예에 따른 추출물 각각을 농도별로 정제수에 녹여 100 μL로 한 시료액을 섞은 후, 효소액 20 μL를 넣어 25℃ 항온수조에서 15분간 반응시켜 ρ-nitroaniline의 생성량을 ELISA reader를 사용하여 파장 405 nm에서 측정한다. A method for measuring the activity of Elastase, an enzyme that degrades elastin, is a method of measuring the activity of ρ-nitroaniline using N-Succinyl-Ala-Ala-Ala-Ala-Ala- And measuring absorbance at a wavelength of 410 nm to measure elasstase activity. The buffer solution was pH 8.0, 0.267 M Trizma-HCl (Sigma), the substrate solution was 8.8 mM N-Succinyl- (Ala) 3 ρ-nitroaniline (Sigma), and the enzyme solution was 10 μg / Respectively. After mixing 20 μL of the buffer solution and 20 μL of the substrate solution and 20 μL of the enzyme solution prepared by dissolving each of the extracts according to each of the above examples into purified water to make 100 μL, the reaction was carried out in a constant temperature water bath at 25 ° C. for 15 minutes to obtain ρ-nitroaniline Is measured at a wavelength of 405 nm using an ELISA reader.
한편, 상기 엘라스테이즈 활성도를 측정하기 위한 대조군은 생약재 추출물 대신 정제수를 넣어 같은 방법으로 측정하였으며, 효소액 대신 정제수를 넣어 각각에 대한 색 보정값을 얻은 경우를 설정하였고, 비교군으로서 일반적인 엘라스테이즈 저해제로 잘 알려진 ursolic acid를 사용하였다(참고문헌: Lim, Suk-Won외, The effect of two terpenoids, ursolic acid and oleanolic acid on epidermal permeability barrier and simultaneously on dermal functions, 대한화장품학회지, 29(2), 205-232 (2003)). The control group for measuring the activity of the above Elastase activity was prepared by adding purified water instead of the herbal medicine extract and measuring by the same method. The case where the color correction value was obtained by adding purified water instead of the enzyme solution was set, Ursolic acid was used as an inhibitor (Lim, Suk-Won et al., The effect of two terpenoids, ursolic acid and oleanolic acid on epidermal permeability barrier and simultaneously on dermal functions, Journal of the Society of Cosmetic Scientists, 29 (2) 205-232 (2003)).
하기 [수학식 3]를 이용하여 엘라스테이즈 활성저해율을 수치로 계산하여 하기 [표 2]에 나타내었다. 하기 [표 2]에서, IC50은 엘라스테이즈 활성저해율 50%를 달성하기 위해 소요되는 추출물 시료의 농도로서 다른 성분물질과 상대적으로 비교할 때 사용하는 수치로서 값이 작을수록 저해능이 높음을 나타낸다.
The inhibition rate of Elastase activity was calculated numerically using the following formula (3), and the results are shown in Table 2 below. In the following [Table 2], the IC 50 is the concentration of the extract sample required to achieve 50% of the inhibition rate of Elastase activity, which is a value used in comparison with other ingredient materials.
IC50(㎍/mL)Ella Stage active low performance
IC 50 ([mu] g / mL)
상기한 [표 2]에 나타낸 바와 같이, 엘라스테이즈 활성저해 효과는 실시예 대부분에서 좋은 효과를 보였으며, 특히 부틸알코올 분획물에서 상대적으로 엘라스테이즈 활성저해 효과가 현저히 우수한 것으로 확인되었으며, 이러한 결과는 일반적인 엘라스테이즈 저해제로 알려진 ursolic acid의 효과보다 더 양호한 것으로 확인되었다.
As shown in the above Table 2, the effect of inhibiting the activity of Elastase was shown to be good in most of the Examples, and especially in the fraction of butyl alcohol, it was confirmed that the effect of inhibiting the activity of Elastase was remarkably excellent. Was found to be better than the effect of ursolic acid, which is known as a general elastase inhibitor.
<< 실험예Experimental Example 3> 3> 콜라게네이즈Collagenase (( MMPMMP -1) 발현 저해효과 시험-1) expression inhibitory effect test
본 발명의 상기 각 실시예 2-(1), 2-(2), 2-(3)에 따라 수득된 적하수오 부정근 추출물을 시료로 하여 UV-A 조사에 의해 발현이 증가되는 콜라게네이즈(MMP-1)의 발현저해 효과를 실시하였다.The collagenase which is increased in expression by UV-A irradiation using the extract of the present invention obtained in accordance with each of Examples 2- (1), 2- (2) and 2- (3) MMP-1).
본 실험예에 사용된 정상 사람 섬유아세포(HS68, CRL 1635)는 ATCC으로부터 분양받아 사용하였다.
The normal human fibroblast (HS68, CRL 1635) used in this experiment was purchased from ATCC.
*세포를 10% 소혈청과 1% 항생제를 첨가한 DMEM (Dulbecco's Modified Eagle's Medium)에 1 x 105 세포의 밀도로 접종하고 하루 동안 5% CO2, 37℃에서 배양시켰다. 자외선 챔버를 이용하여 배양한 섬유아세포에 영향을 주지 않는 범위에서 UV-A를 조사한 후 시료가 첨가된 배지로 교환하여 48시간 배양한 다음 배지를 회수하여 콜라게네이즈 측정기구(미국 아머샴파마샤 사)를 이용하여 생성 정도를 측정하였다. 먼저 콜라게네이즈 1차 항체가 균일하게 도포된 96-웰 플레이트에 상기 세포배양액을 넣고 3시간 동안 항원-항체 반응을 실시하였다. 3시간 후 발색단이 결합된 2차 콜라게네이즈 항체를 넣고 다시 1시간 동안 반응시켰다. 그 후 발색유발물질을 넣어 실온에서 30분간 발색을 유발시키고, 다시 1 M 황산을 넣어 발색을 중지시켜 ELISA reader를 사용하여 파장 450 nm에서 측정하였다. 측정값은 하기 [수학식 4]에 의해 콜라게네이즈 발현 정도를 나타내었으며, 비처리군의 콜라게네이즈 발현 정도를 100으로 하여 [표 3]에 나타내었다. 이때 시료를 처리하지 않은 세포 배양액의 반응 흡광도를 대조군으로 하였으며, 비교군으로서 일반적인 콜라게네이즈 발현저해제로 잘 알려진 EGCG를 사용하였다.
Cells were inoculated at a density of 1 × 10 5 cells in DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 10% bovine serum and 1% antibiotic and incubated at 37 ° C in 5% CO 2 for 1 day. UV-A was irradiated within the range not affecting the fibroblasts cultured with the ultraviolet chamber, the medium was replaced with the medium supplemented with the sample, and the medium was cultured for 48 hours. Then, the medium was recovered and the collagenase measuring apparatus (Amersham Pharmacia The degree of production was measured by using a microscope. First, the cell culture medium was added to a 96-well plate uniformly coated with collagenase primary antibody, and antigen-antibody reaction was performed for 3 hours. After 3 hours, the second collagenase antibody conjugated with chromophore was added and reacted again for 1 hour. Then, the color development inducing substance was added to induce the coloration at room temperature for 30 minutes, and again the color development was stopped by adding 1 M sulfuric acid, and measurement was made at 450 nm using an ELISA reader. The measured values showed the degree of collagenase expression by the following formula (4), and the degree of collagenase expression in the untreated group was taken as 100, which is shown in Table 3 below. At this time, the reaction absorbance of the cell culture without treatment of the sample was used as a control, and EGCG, which is well known as a general collagenase expression inhibitor, was used as a comparative group.
상기 [표 3]에 나타낸 바와 같이, 콜라게네이즈 발현저해 효과는 실시예 대부분에서 좋은 효과를 보였으며, 특히 에칠아세테이트 분획물에서 상대적으로 콜라게네이즈 발현저해 효과가 현저히 우수한 것으로 확인되었으며, 이러한 결과는 일반적인 콜라게네이즈 발현저해제로 알려진 EGCG의 효과보다 더 양호한 것으로 확인되었다.As shown in Table 3, the collagenase inhibitory effect was good in most of the examples, and in particular, the ethyl acetate fraction was found to have a relatively excellent inhibitory effect on collagenase expression, Was found to be better than the effect of EGCG, known as a common collagenase expression inhibitor.
이의 결과로 보아, 본 발명이 이루고자 하는 기술적 과제로서 본 발명에 따른 적하수오 부정근 추출물은 주름개선효과를 검정하는 항산화, 엘라스테이즈 활성저해 효과, 콜라게네이즈 발현저해 효과를 가지며, 특히 적하수오 부정근 추출물의 에칠아세테이트 및 부틸알코올 분획물은 일반적으로 잘 알려진 항산화제인 α-tocopherol과 엘라스테이즈 활성저해제인 ursolic acid, 콜라게네이즈 발현저해제인 EGCG의 효과 보다 더 우수한 효과를 확인함으로써, 우수한 피부 주름개선 효과가 있음을 확인할 수 있었다.
As a result, it is an object of the present invention to provide an antioxidant, an inhibitor of Elastase activity and an inhibitor of collagenase expression, The ethyl acetate and butyl alcohol fractions of the extracts showed better effects than α-tocopherol, ursolic acid, which is a well-known antioxidant, and EGCG, an inhibitor of collagenase expression, .
<제형 <Formulation 실시예Example 1> 제형 1> Formulation 실시예Example 1 및 그 1 and 비교예Comparative Example 1 One
상기 실시예 2-(2)에 따른 생약재 추출물을 함유한 피부 주름개선용 화장수의 성분구성을 하기 [표 4]와 같이 구성하여 제조하였다. 이때, 성분함량의 단위는 중량%이다.
The composition of the skin lotion wrinkle-improving lotion containing the herbal medicine extract according to Example 2- (2) was constructed as shown in Table 4 below. Here, the unit of the component content is% by weight.
상기 [표 4]의 각 성분 번호로 구별된 성분 중에서, 먼저 성분 1(정제수)에 성분 2와 3을 교반 분산시킨 후, 성분 4 내지 6을 가하고, 성분 8 내지 10을 성분 7에 용해시킨 물질과 성분 11을 차례로 가하여 혼합하는 방식으로 제조하였다. Of the components identified by the respective component numbers in Table 4, the components 2 and 3 were first dispersed with stirring in the component 1 (purified water), then the components 4 to 6 were added, and the components 8 to 10 were dissolved in the component 7 And component 11 were added in this order and mixed.
상기 제형 실시예 1에 대한 그 비교예 1은 성분 11인 실시예 2-(2)에 따른 생약재 추출물을 제외한 나머지 성분 구성이나 제조방법은 동일하게 진행하여 제조한 것을 설정하였다.
In Comparative Example 1 of the above-mentioned Formulation Example 1, the other components except for the herbal medicine extract according to Example 2- (2), which is the component 11, were prepared by proceeding in the same manner.
<제형 <Formulation 실시예Example 2> 제형 2> Formulation 실시예Example 2 및 그 2 and 비교예Comparative Example 2 2
상기 실시예 2-(2)에 따른 생약재 추출물을 함유한 탄력로션의 성분구성을 하기 [표 5]과 같이 구성하여 제조하였다. 이때, 성분함량의 단위는 중량%이다.
The composition of the elastic lotion containing the herbal medicine extract according to Example 2- (2) was constructed as shown in Table 5 below. Here, the unit of the component content is% by weight.
하기 [표 6]의 각 성분 번호로 구별된 성분 중에서, 먼저 성분 1 내지 7을 70℃의 온도에서 가열 용해시킨 다음, 성분 8 내지 11을 성분 12에 용해 분산시켜 70℃로 가열한 것에 유화한다. 이후, 상기 유화한 것을 성분 13으로 중화하고, 56℃의 온도로 냉각한 후, 성분 14를 가하여 교반하고 실온으로 냉각하여 제조하였다. Components 1 to 7 are first melted by heating at a temperature of 70 DEG C, and then Components 8 to 11 are dissolved and dispersed in Component 12 and emulsified by heating at 70 DEG C . Thereafter, the emulsified product was neutralized with a component 13, cooled to a temperature of 56 캜, and then added with component 14, followed by stirring and cooling to room temperature.
상기 제형 실시예 2에 대한 그 비교예 2는 성분 14인 실시예 2-(2)에 따른 생약재 추출물을 제외한 나머지 성분 구성이나 제조방법은 동일하게 진행하여 제조한 것을 설정하였다.
In Comparative Example 2 of the above-mentioned Formulation Example 2, it was set that the remaining components except for the herbal medicine extract according to Example 2- (2), which is the component 14, were produced by proceeding in the same manner.
<제형 <Formulation 실시예Example 3> 제형 3> Formulation 실시예Example 3 및 그 3 and 비교예Comparative Example 3 3
상기 추출 실시예 2-(2)에 따른 생약재 추출물을 함유한 탄력영양크림의 성분구성을 하기 [표 6]과 같이 구성하여 제조하였다. 이때, 성분함량의 단위는 중량%이다.
The composition of the elastic nutrition cream containing the herbal medicine extract according to the extraction example 2- (2) was prepared as shown in Table 6 below. Here, the unit of the component content is% by weight.
상기 [표 6]의 각 성분 번호로 구별된 성분 중에서, 먼저 성분 1 내지 7을 70 ℃의 온도에서 가열 용해시킨 다음, 성분 9 내지 12를 성분 13에 용해 분산시켜 70 ℃로 가열한 것에 유화한다. 이후, 상기 유화한 것을 56℃의 온도로 냉각한 후, 성분 14를 가하여 교반하고 실온으로 냉각하여 제조하였다. Of the components identified by the respective component numbers in Table 6, the components 1 to 7 are first dissolved by heating at a temperature of 70 캜, and then the components 9 to 12 are dissolved and dispersed in the component 13 and emulsified by heating at 70 캜 . Thereafter, the emulsified product was cooled to a temperature of 56 ° C, and then Component 14 was added to the resulting mixture, followed by cooling to room temperature.
상기 제형 실시예 3에 대한 그 비교예 3은 성분 14인 실시예 2-(2)에 따른 생약재 추출물을 제외한 나머지 성분 구성이나 제조방법은 동일하게 진행하여 제조한 것을 설정하였다.In Comparative Example 3 of the above-mentioned Formulation Example 3, it was set that the other components except for the herbal medicine extract according to Example 2- (2), which is the component 14, were produced by proceeding in the same manner.
이상에서 설명된 본 발명의 최적 실시예들이 개시되었다. 여기서 특정한 용어들이 사용되었으나, 이는 단지 본 발명을 설명하기 위한 목적에서 사용된 것이지 의미한정이나 특허 청구범위에 기재된 본 발명의 범위를 제한하기 위해 사용된 것이 아니다.
Best modes of carrying out the invention have been disclosed. Although specific terms are employed herein, they are used for the purpose of describing the invention only and are not used to limit the scope of the invention, which is defined in the claims or the claims.
<< 실험예Experimental Example 4> 피부노화 방지 및 피부자극 평가 4> Prevention of skin aging and evaluation of skin irritation
본 발명에 따른 피부 주름 개선 및 노화방지용 화장료 조성물의 피부 주름개선효과 및 피부자극을 평가하기 위하여, 상기 제형 실시예 3과 비교예 3에서 제조된 탄력영양크림을 이용하여 관능시험을 실시하였다. In order to evaluate the skin wrinkle improving effect and skin irritation of the cosmetic composition for improving skin wrinkles and aging according to the present invention, a sensory test was conducted using the elastic nutrition cream prepared in Formulation Example 3 and Comparative Example 3.
관능시험은 피부의 주름개선효과 항목에 대하여는 제형 실시예 3의 탄력영양크림을 기준으로 비교예 3의 탄력영양크림이 나타내는 주름개선효과를 상대적으로 평가하게 하였고, 피부자극에 대한 관능평가는 피부의 가려움, 따가움 및 홍반 등의 현상을 평가하게 하였다. 평가는 매우 우수(5점), 우수(4점), 보통(3점), 나쁨(2점), 매우 나쁨(1점)의 오점법 기준에 의거하여 수행하였으며, 그 결과를 하기 [표 7]에 나타내었다. 하기 [표 7]에서 피부자극은 피부자극이 없는 정도를 나타낸다.
In the sensory test, the effect of improving the wrinkles of the skin was evaluated relative to the wrinkle improving effect of the elastic nutrition cream of Comparative Example 3 on the basis of the elastic nutrition cream of Formulation Example 3, Itching, burning, and erythema. The evaluation was carried out according to the blotting law standards of excellent (5 points), excellent (4 points), normal (3 points), poor (2 points) and very poor (1 point) ]. In Table 7 below, skin irritation represents a degree of no skin irritation.
상기 [표 7]에 나타낸 바와 같이, 본 발명에 따른 제형예 3의 화장료 조성물에 대한 피부자극 평가점수는 4.50점으로 매우 양호하게 평가되어, 비교제형예 3과 마찬가지로 피부자극 정도가 낮아 피부 안전성이 우수함을 확인할 수 있었다.As shown in the above Table 7, the skin irritation evaluation score of the cosmetic composition of Formulation Example 3 according to the present invention was extremely good evaluated at 4.50 points, and skin irritation degree was low similarly to Comparative Formulation Example 3, And it was confirmed that it is excellent.
또한, 비교제형예 3 대비 제형예 3의 화장료 조성물이 가진 상대적인 피부의 주름개선효과는 평가점수 4.60점으로 개선 정도가 매우 우수함을 알 수 있었다.
In addition, the comparative skin wrinkle improving effect of the cosmetic composition of Formulation Example 3 versus Comparative Formulation Example 3 was 4.60 points, which was found to be excellent.
<< 실험예Experimental Example 5> 피부의 안전성 실험 5> Safety test of skin
상기한 본 발명의 실시예 2-(2)에 따른 적하수오 부정근 추출물과 상기 적하수오 부정근 추출물을 포함하는 화장료 조성물인 제형 실시예 3의 피부 안전성, 즉 피부반응의 관찰을 통해서 자극 혹은 알레르기성 반응의 발생 여부를 알아보기 위하여 한국식품의약품안전처 기준 피부안전성 검사법에 따라 인체첩포시험을 실시하였다.The skin safety of Formulation Example 3, which is a cosmetic composition comprising the extract of the present invention of Example 2- (2) of the present invention and the above-mentioned extract of the present invention, i.e., skin reaction, To assess the occurrence of skin lesions, we conducted a human skin patch test according to the Korea Food & Drug Administration 's Criteria for Skin Safety Test.
피험자로 20세 이상 50세 이하의 건강한 성인 남, 여 30명을 선정하였고, 첩포시험은 대상자 상박 내측에 첩포를 부착하였으며 48시간이 지난 후 첩포를 제거하였다. 약 60분간 안정을 취하도록 한 후 첫 판독을 시행하였고, 첩포 부착 후 96시간이 경과한 후 2차 판독을 시행하였다. 판정기준은 하기 [표 8]에 나타낸 바와 같다.
Thirty healthy male and female subjects aged 20 to 50 years old were selected as test subjects. Patch tests were performed on the inside of the upper abdomen of the subjects and after 48 hours, the epidermal patches were removed. The first reading was performed after about 60 minutes of stabilization, and the second reading was performed after 96 hours of attachment. The criteria are shown in Table 8 below.
첩포 부착 후 48시간과 96시간에 판독한 결과를 하기 [수학식 5]를 이용하여 시료에 대한 피부 반응도를 산출하였다.
The skin response to the sample was calculated using the formula (5) as the result of reading at 48 hours and 96 hours after attaching the patch.
첩포시험의 검사 결과에 근거하여 계산된 양성 반응을 보인 시료의 피부 자극도를 하기 [표 9]에 나타내었다.
The skin irritation of the samples showing the positive reaction calculated based on the test results of the patch test is shown in Table 9 below.
(1% in Propanediol)Example 2- (2)
(1% Propanediol)
상기 [표 9]에 제시된 바와 같이, 본 발명의 적하수오 부정근 추출물인 실시예 2-(2)와 상기 적하수오 부정근 추출물을 포함하는 화장료 조성물인 제형 실시예 3에 대한 인체첩포시험에서 상기 [표 10]에 나타낸 피부 반응도 판정 기준에 의하면 무자극으로 민감한 피부에 사용해도 좋은 결과로 나타났다. 따라서 상기한 본 발명의 생약재추출물 및 이를 포함하는 화장료 조성물은 피부부작용이 없는 안전한 성분으로 나타났다.
As shown in the above Table 9, in the human skin test of Example 2, which is the cosmetic composition comprising Example 2 (2) of the present invention and Comparative Example 2 (2) of the present invention, According to the skin response criteria shown in [10], it could be used for sensitive skin with no stimulation. Therefore, the herbal medicine extract of the present invention and the cosmetic composition containing the herb extract are safe ingredients without skin side effects.
이상 설명한 바와 같이 본 발명은 적하수오 부정근 추출물을 유효성분으로 함유한 피부주름개선 기능성 화장료 조성물을 제공하는 뛰어난 효과가 있으므로 화장품 산업상 매우 유용한 발명인 것이다.INDUSTRIAL APPLICABILITY As described above, the present invention is an extremely useful invention in the cosmetics industry because it has an excellent effect of providing a skin wrinkle-improving functional cosmetic composition containing an effective extract of an algae root extract.
Claims (6)
A cosmetic composition for the treatment of wrinkles for improving skin wrinkles characterized in that the cosmetic composition of claim 5 has any one of formulations selected from skins, lotions, essences, creams, packs, foundations and makeup bases
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150103987A KR101824770B1 (en) | 2015-07-22 | 2015-07-22 | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150103987A KR101824770B1 (en) | 2015-07-22 | 2015-07-22 | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140071624 Division | 2014-06-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150143375A KR20150143375A (en) | 2015-12-23 |
KR101824770B1 true KR101824770B1 (en) | 2018-02-02 |
Family
ID=55082525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150103987A KR101824770B1 (en) | 2015-07-22 | 2015-07-22 | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101824770B1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3069161B1 (en) | 2017-07-21 | 2019-08-30 | Plant Advanced Technologies Pat | ROTARY POLYGONUM MULTIFLORUM EXTRACTS AND USES THEREOF |
KR102093667B1 (en) | 2018-02-23 | 2020-03-27 | 대한바이오팜 주식회사 | Composition for anti-wrinkle, skin whitening and antioxidation comprising medicinal herb extract |
KR102047461B1 (en) | 2018-02-23 | 2019-11-21 | 주식회사 엘지생활건강 | Composition for improving wrinkle comprising Symplocarpus foetidus extract or fractions thereof |
KR102073349B1 (en) | 2019-03-11 | 2020-02-05 | 대한바이오팜 주식회사 | Composition for anti-wrinkle, skin whitening and antioxidation comprising medicinal herb extract |
KR102406981B1 (en) * | 2020-11-20 | 2022-06-09 | 재단법인 전주농생명소재연구원 | Composition for improving skin wrinkle comprising extract of Semiaquilegia adoxoides having antioxidant and anti-inflammatory activity as effective component |
KR102438804B1 (en) | 2022-04-22 | 2022-09-01 | 주식회사 아트앤퍼퓸 | Body lotion composition prepared using ginseng oil and frankincense oil for wrinkle improvement and skin aging prevention, and method for preparing the same |
-
2015
- 2015-07-22 KR KR1020150103987A patent/KR101824770B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20150143375A (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102126469B1 (en) | Cosmetic Compositions comprising extract of Dendrobium candidum flower extract | |
KR101824770B1 (en) | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract | |
KR100844516B1 (en) | Cosmetic composition containing Astragalus extract | |
KR100825450B1 (en) | Cosmetic composition for improving skin wrinkles containing duct extract | |
KR20110098124A (en) | Composition containing ginseng fruit extract using foam | |
KR102158780B1 (en) | Composition for improving skin comprising natural material extract | |
KR20170037570A (en) | Composition for Preventing Skin Aging and Improving Skin Wrinkle Comprising Extract of Perilla Leaf | |
KR102063686B1 (en) | Skin external composition containing extract of soybean root | |
KR20140095122A (en) | A composition for inhibiting degradation of collagen or promoting synthesis of collagen comprising barley extract or eriodictyol | |
KR101189989B1 (en) | Cosmetic composition containing a sentence-like extract as an active ingredient | |
KR20120092229A (en) | Cosmetic composition comprising the fermented extracts of tissue cultures of brassica napus l, punica granatum and panax ginseng) | |
KR101803757B1 (en) | Cosmetic composition containing natural complex fermented extracts | |
KR101700105B1 (en) | A composition for antioxidating, whitening and improving wrinkle comprising extracts of false indigo | |
KR101873025B1 (en) | Cosmetic composition containing complex extract of oriental plants | |
KR101852252B1 (en) | Method for culturing Lilium Candidum Cell and Functional skin external application comprising Lilium Candidum Cell Culture Extract | |
KR20050092313A (en) | Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation | |
KR20120118946A (en) | Skin whitening complex containing trihydroxyisoflavone and glycyrrhiza uralensis extracts | |
KR101550309B1 (en) | Antiaging cosmetic composition containing fermented green tomato extract | |
KR101924446B1 (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
KR20170013588A (en) | Composition for skin whitening and anti-wrinkle comprising Cistanche deserticola extract as effective component | |
KR101810825B1 (en) | Cosmetics compositions containing fermentation extract from leaf Daphniphyllum macropodum Miq. | |
KR101583052B1 (en) | Anti-wrinkle cosmetic composition containing Polygonum multiflorum extract | |
KR20160003916A (en) | Cosmetic composition for whitening or improving the facial color containing herb extracts | |
KR101980144B1 (en) | A composition for antioxidating, whitening and improving wrinkle comprising extracts of pleurotus salmoneostramineus | |
KR102137952B1 (en) | Cosmetic composition with skin soothing effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20150722 Patent event code: PA01071R01D Filing date: 20140612 Application number text: 1020140071624 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20151019 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160929 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20170530 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20160929 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20151019 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
AMND | Amendment | ||
PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20170530 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20161122 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20151218 Comment text: Amendment to Specification, etc. |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170720 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
PX0701 | Decision of registration after re-examination |
Patent event date: 20180118 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20170919 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20170629 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20170530 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20161122 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20151218 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180126 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20180126 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20210121 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20220106 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20230103 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20240103 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20241230 Start annual number: 8 End annual number: 8 |